St. Petersburg-based pharmaceutical company "Geropharm" has terminated its agreement with Uzbekistan's Zuma Pharma, according to the company's press service as reported by Kommersant St. Petersburg. The Russian company had intended to utilize Zuma Pharma's production facilities to localize insulin production in Uzbekistan. However, the parties failed to reach mutually agreeable terms. While the reasons for contract termination remain undisclosed due to a non-disclosure agreement, "Geropharm" remains committed to producing insulin in the country and is actively searching for a new industrial partner.
Terminating the partnership with Zuma Pharma will not impede "Geropharm's" plans to localize analogue insulin production within Uzbekistan. The company's press service assured uninterrupted drug supply to the country until a new partner is identified. Last year, "Geropharm" delivered 33,000 packages of insulin to Uzbekistan.
In April 2022, a project for the production and supply of insulin drugs was agreed upon by First Deputy Minister of Health of Uzbekistan Amrillo Inoyatov, Sales Director of "Geropharm" Vladimir Skornyakov, and Zuma Pharma founder Nodir Yunusov.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)